Last updated on July 2019

To Evaluate the Safety and Tolerability of Atogepant 10mg 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine

Brief description of study

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Clinical Study Identifier: NCT03777059

Find a site near you

Start Over

Primary Care Associates/Synexus Clinical

Anderson, SC United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.